Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder

Value in Health

Volumn 3, Issue 1, 2000, Pages 40-47

  Dardennes, R M ^a   Lafuma, A ^b   Fagnani, F ^b   Pribil, C ^b   Bisserbe, J C ^c   Berdeaux, G ^c  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b CEMKA EVAL   (France)

^c Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Cost analysis; Depression; Prevention

Indexed keywords

MILNACIPRAN;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SUICIDE;

EID: 0034095124     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.31005.x     Document Type: Article

References (52)

1. Murray C, Lopez A (eds.). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020 (1st ed.). Global Burden of Disease and Injury Series. Boston: Harvard University Press, 1996.
2. Murray C, Lopez A (Ed.). Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for Over 200 Conditions (1st ed.). Global Burden of Disease and Injury Series. Boston: Harvard University Press, 1996.
3. MM Weissman Cross-national epidemiology of major depression and bipolar disorder JAMA 276 4 1996 293 299
4. V Kovess S Gysens P Chanoit Une enquête de santé mentale: lenquête santé des Franciliens Ann Méd Psychol 151 1993 624 627
5. DG Blazer RC Kessler MG Gonagle MS Swarte The prevalence and distribution of major depression in a national community sample: the national comorbidity survey Am J Psychiatry 151 1994 979 986
6. N Sartorius A Jablenski W Gulbinat G Ernberg WHO collaborative study: assessment of depressive disorders Psychol Med 10 1980 743 749
7. PE Greenberg LE Stiglin SN Finkelstein ER Berndt The economic burden of depression in 1990 J Clin Psychiatry 54 11 1993 405 418
8. P Boyer R Dardennes A Gerard Y Lecrubier C Le Pen E Weiller Dépression et Santé Publique 1999 Masson Paris
9. JC Bisserbe Long-term evaluation of treatments of depressive states and anxiety disorders Therapie 49 3 1994 251 260
10. Depression Guideline Panel. Depression in primary care, Vol. II. Treatment of major depression. Clinical Practice Guideline, Number 5. AHPCR Publication No. 93-0551. Rockville, MD: Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993.
11. Consensus Development Panel NIMH/NIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences Am J Psychiatry 142 4 1985 469 476
12. WHO Mental Health Collaborating Centers Pharmacotherapy of depressive disorders: a consensus statement J Affect Disord 17 1989 197 198
13. Rouillon F, Warner B, Pezous N, Bisserbe JC, and the Milnacipran Study Group. Milnacipran efficacy in the prevention of recurrent depression: a twelvemonth study. Int Clin Psychopharmacol. In press 2000.
14. Nomenclature générale des actes professionnels 1999 UCANSS Paris
15. Tarif InterMinistériel des Prestations Sanitaires 1999 UCANSS Paris
16. Dictionnaire VIDAL 1999 Editions du VIDAL Paris
17. A Briggs M Sculpher An introduction to Markov modeling for economic evaluation Pharmacoeconomics 13 4 1998 397 409
18. DK Miller SM Homan Determining transition probabilities: confusion and suggestions Med Decis Making 14 1 1994 52 58
19. R Dardennes G Berdeaux A Lafuma Comparison of the cost-effectiveness of Milnacipran, a new SNRI with TCAS and SSRIS: a modeling approach European Psychiatry 3 1999 152 162
20. A Le Pape T Lecomte Aspects Socio-économiques de la Dépression. Evolution 1980–81/1991–92 1996 CREDES Paris
21. P Boyer JM Danion JC Bisserbe Clinical and economic comparison of Sertraline and Fluoxetine in the treatment of depression Pharmacoeconomics 13 1998 157 169
22. Mission Cléry-Mellin. Rapport d'orientation: Des alternatives à l'hospitalization; pour des soins diversifiés et de qualité en psychiatrie. Paris: Ministère des Affaires Sociales, de la Santé et de la Ville, 1995.
23. G Winokur W Coryell M Keller A prospective follow-up of patients with bipolar and primary unipolar affective disorder Arch Gen Psychiatry 50 6 1993 457 465
24. RC Bland Epidemiology of affective disorders: a review Can J Psychiatry 42 4 1997 367 377
25. B Martin MD Keller RW Shapiro Recovery in major depressive disorder: analysis with the life table and regression models Arch Gen Psychiatry 39 8 1982 905 910
26. W Coryell H Akiskal AC Leon The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression-Clinical Studies Arch Gen Psychiatry 51 5 1994 405 410
27. Indicateur statistique 1995. Paris: Caisse Nationale d'Assurance Maladie d'Ile de France, 1997.
28. D Avery G Winokur Mortality in depressed patients treated with electroconvulsive therapy and antidepressants Arch Gen Psychiatry 33 9 1976 1029 1037
29. DW Black G Winokur E Mohandoss Does treatment influence mortality in depressives? A follow-up of 1076 patients with affective disorders Ann Clin Psychiatry 1 1989 165 173
30. J Fawcett W Sheftner D Clarck Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study Am J Psychiatry 144 1 1987 35 40
31. GD Tollefson J Fawcett G Winokur Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders Ann Clin Psychiatry 5 1993 209 224
32. GW Blair-West GW Mellsop ML Eyeson-Annan Down-rating lifetime suicide risk in major depression Acta Psychiatr Scand 95 3 1997 259 263
33. HM Inskip EC Harris B Barraclough Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia Br J Psychiatry 172 1998 35 37
34. SF Anton DA Revicki The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone Psychopharmacol Bull 31 2 1995 249 258
35. EJ Hatziandreu RE Brown DA Revicki Cost utility of maintenance treatment of recurrent depression with Sertraline versus episodic treatment with Dothiepin Pharmocoeconomics 5 3 1994 249 264
36. JD Bentkover JP Feighner Cost analysis of Paroxetine versus Imipramine in major depression Pharmacoeconomics 8 3 1995 223 232
37. MJC Nuijten M Hardens E Souêtre A Markov process analysis comparing the cost-effectiveness of maintenance therapy with citalopram versus standard therapy in major depression Pharmacoeconomics 8 2 1995 159 168
38. M Nuijten L Hadjadjeba C Evans J Van den Berg Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France Pharmacoeconomics 14 4 1998 433 445
39. RF Prien JH Kocsis Long-term management of mood disorders B Kupfer Psychopharmacology—The Fourth Generation in Progress 1995 Raven Press New York
40. DP Doogan V Caillard Sertraline in the prevention of depression Br J Psychiatry 160 1992 217 222
41. Old Age Depression Interest Group How long should the elderly take antidepressant? A doubleblind placebo-controlled study of continuation/prophylaxis therapy Br J Psychiatry 162 1993 175 182
42. JL Terra F Noël Fluvoxamine effective in preventing recurrence of major depression Eur Neuropsychopharmacol 465 1996 1016
43. JB Greenhouse DN Stabgk DJ Kupfer RF Prien Methodologic issues in maintenance therapy clinical trials Arch Gen Psychiatry 48 4 1991 313 318
44. SA Montgomery G Dunbar Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression Int Clin Psychopharmacol 8 1993 189 195
45. F Rouillon D Serrurier HD Miller Prophylactic efficacy of Maprotiline on unipolar depression relapse J Clin Psychiatry 52 10 1991 423 431
46. SA Montgomery JGC Rasmussen P Tanghoj A 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression Int Clin Psychopharmacol 8 1993 181 188
47. P Robert SA Montgomery Citalopram in doses of 20–60 mg is effective in depression relapse prevention Int Clin Psychopharmacol 10 1 1995 29 35
48. C Faravelli A Ambonetti S Pallanti A Pazzali Depressive relapses and incomplete recovery from index episode Am J Psychiatry 143 7 1986 888 891
49. A Georgotas RE McCue TB Cooper A placebocontrolled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients Arch Gen Psychiatry 46 9 1989 783 786
50. SA Montgomery DP Doogan R Burnside The influence of different relapse criteria on the assessment of long-term efficacy of Sertraline Int Clin Psychopharmacol 6 2 1991 37 46
51. ME Thase AD Simons J McGeary Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment Am J Psychiatry 149 8 1992 1046 1052
52. T Lebrun JP Marissal JC Sailly Mesure de l'intérêt économique de la dialyse hors centre: le cas de la dialyse péritonéale continue ambulatoire Rev Epidemiol Sante Publique 45 1997 493 507